PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-325

The rising prevalence of neurological diseases may possibly be attributed to western lifestyle factors.

Whilst Monepantel can have a potential therapeutic benefit by reducing toxic protein build up, it would be an advantage to have a healthier baseline population in the first place. I'm a strong believer that the typical western diet and attitude to physical activity may have a part to play in reversing the increase in neurological diseases.

I would love to have a conversation with Dr's Mathers & Rowe to ask if they recommend dietary changes to MND patients upon presentation to their clinics. It would be interesting to see if any natural anti-inflammatory supplement such as turmeric could work in conjunction with Monepantel to enhance positive outcomes.

The cause of MND is unknown, and I am not for a moment suggesting our trial patients are suffering their conditions due to lifestyle. My only observation is that a holistic approach to treatment which includes Monepantel could be beneficial.

I agree that the ever increasing Alzheimer's market size presents a huge opportunity for PAA.

But on the flip side, it's sad that so many people will ultimately develop this disease.

Good health to all....Cheers, Thrifty